Navigation Links
ArborGen and Senesco Announce Wood Quality Results

SUMMERVILLE, S.C., July 7 /PRNewswire/ -- ArborGen, LLC, a leader in forest tree improvement technologies, today announced wood quality results from ongoing field trials that are utilizing technology in-licensed from Senesco Technologies, Inc. (NYSE AMEX: SNT). The two companies had previously announced that trees that incorporate Senesco technology have shown significantly enhanced growth rates in 3-year-old field trials.

Selected trees from the field trials were harvested and their wood chemistry and density was assessed. There were no differences in key economic characteristics of wood, such as lignin, cellulose, and specific gravity, between the trees with the enhanced growth attributes and untreated control trees. This is good news as fast tree growth is often associated with lower wood quality.

"With several years of positive field trials, Senesco's technology has certainly given us confidence in the consistency of performance of this technology," said Barbara Wells, Ph.D., president and CEO of ArborGen. "Our collaboration with Senesco continues to produce very promising results that we expect will ultimately add to our portfolio of forestry products."

Bruce Galton, President and CEO of Senesco, said, "We believe ArborGen's results represent another step toward the commercial validation of our technology in the hands of our licensing partners. Partnering with companies with ArborGen's expertise allows for development of our technology for agricultural applications, while our internal research and development remains focused on our near term goal of filing an Investigational New Drug application with the FDA for our ongoing oncology work in multiple myeloma. We believe these results further reaffirm the broad applicability of Senesco's technology."

About ArborGen, LLC

ArborGen is a leader in tree improvement and the commercial production of trees. We are dedicated to helping the global forest industry meet the growing demand for wood, pulp & paper, and energy in a more productive and sustainable way. Enabling more wood to be grown on less land helps conserve the world's native forests in all their beauty, diversity and complexity. With one of the world's most extensive tree germplasm resources, ArborGen uses both traditional breeding and advanced genetic technologies, to discover and produce high yield seedlings for our customers, allowing our customers to significantly increase the productivity of their forests and manufacturing processes. Our mission is to deliver superior performing trees through innovative science and world class customer service -- every tree, every time. For more information, please visit

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of Senesco to consummate a financing; the development of Senesco's gene technology; the approval of Senesco's patent applications; the successful implementation of Senesco's research and development programs and joint ventures; the success of Senesco's license agreements; the acceptance by the market of Senesco's products; success of Senesco's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, Senesco's ability to meet its funding milestones under its financing transaction, Senesco's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in Senesco's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Senesco's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Senesco undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Senesco Investor Contact:
    Brian Ritchie
    Phone: (212) 850-5600

    ArborGen Contact:
    Nancy M. Hood
    Director of Communication & Public Affairs
    Phone: (843) 851-5077
    Cell: (843) 323-1509

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
2. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
3. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
4. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
5. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
6. Senesco Technologies to Present at BIO 2008 Business Forum
7. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
8. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
9. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
10. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
Post Your Comments:
(Date:10/8/2015)... October 8, 2015 ... --> Goldman Small Cap Research, a ... cap and microcap sectors, announced today that it ... PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly ... and preparing treatments for cancer and diabetes. To ...
(Date:10/8/2015)... 2015 The 2015 Nobel Prize in Chemistry ... at Dallas. Aziz Sancar , who earned his PhD ... in 1977, is one of three scientists who received the ... repair damaged DNA on a molecular level.  --> Aziz ... from UT Dallas in 1977, is one ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... Oct. 8, 2015  Today the Wyss Institute for ... of its start-up company Opsonix Inc. The ... Harvard,s Office of Technology Development (OTD) and Opsonix ... therapy for clinical use. --> ... a million people every year in the U.S. — ...
Breaking Biology Technology:
... WAYNE, Pa., March 7, 2012 Molecular Detection ... to increase the speed and accuracy of infectious ... a $1.5 million financing.  The funds are primarily ... panels for the detection of sepsis and gastrointestinal ...
... HAWTHORNE, N.J., March 6, 2012   Proteonomix, Inc. ... definitive agreements with certain institutional investors, pursuant to which ... Series E convertible preferred stock at an aggregate purchase ... a total of  895,291 shares of Proteonomix common stock) ...
... researchers including Drexel University,s Dr. Yury Gogotsi has given ... functions of the electrodes of supercapacitors the low-cost, ... and many other applications. In a piece published in ... Gogotsi, and his collaborators from universities in France and ...
Cached Biology Technology:
(Date:10/9/2015)... ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> ) has announced ... S6 Fingerprint Sensor - Reverse Costing Analysis" ... Research and Markets ( ) ...
(Date:10/8/2015)... , Oct. 8, 2015 Synaptics ... human interface solutions, announced today that it will ... fiscal 2016 on Thursday, October 22, 2015, after ... a corresponding conference call for analysts and investors ... which management may discuss forward-looking information.    ...
(Date:10/8/2015)... , 8. Oktober 2015 Die ... tätiges Unternehmen des Bereiches Tracking, hat heute ... der Gefängnisbehörde Virginias (Department of Corrections – ... Überwachungsdienste für alle Strafen geliefert werden, die ... , Präsident für den Amerikanischen Kontinent der ...
Breaking Biology News(10 mins):
... Finland have in collaboration with the University of Turku, ... and Pharmatest Services Ltd, discovered a novel mechanism regulating ... that heparin-like compounds can potentially be used to inhibit ... were published on the Molecular Cancer Research ...
... of Australian and US scientists has found there has been ... found off the coast of Antarctica.,Comparing detailed measurements taken during ... to historical data dating back to 1970, scientists estimate there ... in the volume of Antarctic Bottom Water, the cold dense ...
... San Diego has identified an approved arthritis drug that is ... could offer a low-dose, low cost treatment for the amoebic ... Based on these results, the team has received Orphan Drug ... Food and Drug Administration, and has applied for approval to ...
Cached Biology News:
... Highly efficient delivery of siRNA while ... Electroporate up to 96 samples simultaneously ... from cell harvest to post-electroporation incubation ... , Designed for use with ...
100 adhesive strips....
Request Info...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: